

1 **COVID-19 outcomes in hospitalized puerperal, pregnant, and**
2 **neither pregnant nor puerperal women: a population study**

3

4 Fabiano Elisei Serra¹, Rossana Pulcineli Vieira Francisco^{1*}, Patricia de Rossi^{2,3}, Maria de Lourdes
5 Brizot¹, Agatha Sacramento Rodrigues^{1,4*}

6

7 ¹Disciplina de Obstetrícia, Departamento de Obstetrícia e Ginecologia, Faculdade de Medicina da
8 Universidade de São Paulo, São Paulo, São Paulo, Brazil

9 ²Curso de Medicina, Universidade de Santo Amaro (UNISA), São Paulo, São Paulo, Brazil

10 ³Gerência de Medicina Perinatal e Ginecologia, Conjunto Hospitalar do Mandaqui, São Paulo, São
11 Paulo, Brazil

12 ⁴Departamento de Estatística, Universidade Federal do Espírito Santo, Vitória, Espírito Santo, Brazil

13

14 * Corresponding author

15 E-mail: agatha.rodrigues@ufes.br (ASR)

16

17 **Abstract**

18 **Objective** To compare hospitalized reproductive age women with COVID-19 who were pregnant,
19 puerperal, or neither one nor the other in terms of demographic and clinical characteristics and
20 disease progression using Brazilian epidemiological data.

21 **Methods** A retrospective analysis of the records of the Information System of the Epidemiological
22 Surveillance of Influenza of the Health Ministry of Brazil was performed. It included the data of
23 female patients aged 10 to 49 years hospitalized because of severe COVID-19 disease (RT-PCR+ for
24 SARS-CoV-2), from February 17, 2020 to January 02, 2021. They were separated into 3 groups:
25 pregnant, puerperal, and neither pregnant nor puerperal. General comparisons and then
26 adjustments for confounding variables (propensity score matching [PSM]) were made, using
27 demographic and clinical characteristics, disease progression (admission to the intensive care unit
28 [ICU] and invasive or noninvasive ventilatory support), and outcome (cure or death). Deaths were
29 analyzed in each group according to comorbidities, invasive or noninvasive ventilatory support, and
30 admission to the ICU.

31 **Results** As many as 40,640 reproductive age women hospitalized for COVID-19 were identified:
32 3,372 were pregnant, 794 were puerperal, and 36,474 were neither pregnant nor puerperal.
33 Groups were significantly different in terms of demographic data and comorbidities. Pregnant and
34 puerperal women were less likely to be symptomatic than the women who were neither one nor
35 the other. Pregnant women, however, had a higher frequency of cough, anosmia, and ageusia.
36 Puerperal women had a worse prognosis than pregnant women with respect to admission to the
37 ICU, invasive ventilatory support, and death.

38 **Conclusion** Puerperal women were at a higher risk for serious outcomes (need for the ICU, need for
39 invasive and noninvasive ventilatory support, and death) than pregnant women.

40

41 **Introduction**

42 COVID-19 is an infectious disease caused by the new coronavirus (SARS-CoV-2), and it has a clinical
43 spectrum ranging from absence of symptoms to severe illness and death. Widespread contagion

44 and the ability of the virus to disseminate led the World Health Organization (WHO) to declare a
45 pandemic state in March 2020 [1].The high incidence has had a tremendous socioeconomic impact
46 worldwide. One day prior to the submission of this article (June 28, 2021), globally, there were
47 more than 180 million confirmed cases of COVID-19 and 3,923,238 deaths [2].

48 Since the beginning of the pandemic, the infection has been studied in the obstetric population to
49 understand its consequences and to prevent adverse maternal-fetal outcomes. The initial
50 publications describing COVID-19 cases in pregnant women in China, Europe, and North America
51 did not report increased severity and deaths compared to the general population [3-9].Subsequent
52 studies, however, showed a higher likelihood of the need for admission to intensive care units
53 (ICUs) and mechanical ventilation [10-14].The first maternal deaths were reported in the United
54 Kingdom, Iran, United States, Mexico, and France [15-19].In Brazil, the high number of maternal
55 deaths due to COVID-19 has been attributed to factors such as high birth rate, poor nutrition and
56 health, difficult access to health services, and insufficient obstetric assistance [20,21].

57 Socioeconomic heterogeneity in Brazil is reflected in the quality of health services and in the
58 availability of hospital and ICU beds, having a great impact on health indicators of both pregnant
59 and puerperal women [22,23].Understanding the disease and evaluating why the prognoses of
60 pregnant and puerperal women have been worse in this pandemic is relevant. We did not find any
61 studies comparing demographic and clinical characteristics and disease progression among
62 pregnant women, puerperal women, and neither pregnant nor puerperal women hospitalized with
63 COVID-19.Therefore, the authors of the present study aim to compare pregnant women, puerperal
64 women, and neither pregnant nor puerperal women according to data related to the SARS-CoV-2
65 infection by using population statistics from SIVEP-Gripe (System of Information about
66 Epidemiological Surveillance of Influenza) of the Health Ministry of Brazil.

67

68 **Materials and methods**

69 A retrospective analysis of the statistics from SIVEP-Gripe, a Brazilian national database containing
70 surveillance data on severe acute respiratory syndrome (SARS) was performed [24].The notification
71 of SARS is compulsory in cases of the flu syndrome (acute respiratory condition, characterized by at
72 least two of the following signs and symptoms: fever [even if reported], chills, sore throat,
73 headache, cough, coryza, and disorders of taste or smell), accompanied by dyspnea/respiratory
74 distress, persistent chest pressure, oxygen saturation (SpO₂)below 95% in room air, or cyanosis. The
75 SIVEP-Gripe is notified of all cases of hospitalization both in public and in private hospitals, as well
76 as of all deaths caused by SARS-CoV-2, irrespective of hospitalization.

77 SIVEP-Gripe records include the following: demographic data (sex, age, skin color/ethnicity,
78 obstetric status, schooling, city of residence); clinical data (signs and symptoms, risk
79 factors/comorbidities); epidemiological data (previous flu vaccination, community-acquired
80 infection, or nosocomial infection); laboratory and etiological diagnoses. There is also information
81 about hospital admission, ICU admission, use of ventilatory support (invasive and noninvasive), and
82 disease outcome (cure or death).

83 Data search covered epidemiological weeks 1 to 53 (December 29, 2019 - January 02, 2021), with
84 the last update on January 11, 2021; however, the first Brazilian records began in epidemiological
85 week 8 (first day of symptoms of the first confirmed case was on February 17, 2020). Search
86 included all data on female patients aged 10 to 49 years hospitalized with COVID-19, confirmed
87 with a positive RT-PCR result for SARS-CoV-2.Cases were excluded if they were unhospitalized or
88 unconfirmed with an RT-PCR for SARS-CoV-2, or if gender or pregnancy status were not recorded.
89 The result was 40,640 women hospitalized with COVID-19 (RT-PCR+) and aged between 10 and 49
90 years, who were divided into two groups: pregnant women (n=3,372) and nonpregnant women

91 (n=37,268). The latter were separated into puerperal (n=794) and neither pregnant nor puerperal
92 (n=36,474) (Figure 1).

93 Variables used in the analysis were age, pregnancy status, comorbidities, schooling, skin
94 color/ethnicity, signs and symptoms, SARI (Severe Acute Respiratory Infection, defined as
95 temperature $\geq 38^{\circ}\text{C}$, cough, and onset in 10 days), SARI without fever, admission to ICU, respiratory
96 support, and outcome (cure or death). Comorbidities reported were chronic cardiovascular, renal,
97 neurological, hematologic, hepatic, and respiratory diseases, asthma, obesity, diabetes, and
98 immunosuppression. Fever, cough, sore throat, dyspnea, respiratory discomfort, $\text{SpO}_2 < 95\%$,
99 diarrhea, vomiting, abdominal pain, fatigue, anosmia, and ageusia were the signs and symptoms.
100 Deaths were analyzed individually according to comorbidities, invasive and noninvasive respiratory
101 support, and admission to ICU.

102 SIVEP-Gripe records are publicly available anonymized data. Therefore, according to Brazilian Ethics
103 regulatory requirements, there is no need for ethical approval by an Institutional Review Board.

104

105 **Data analysis**

106 Quantitative variables were summarized as mean and standard deviation. Qualitative variables
107 were displayed as absolute frequencies (n) and category percentages (%).

108 Nonparametric Kruskal-Wallis test was applied to compare the three study groups in terms of
109 quantitative variables. Chi-square test was used to evaluate the association between groups and
110 qualitative variables. Odds Ratio (OR) was considered as a measure of association to compare the
111 relative odds of the occurrence of the outcome of interest with a 95% confidence interval (95%CI).

112 Propensity score matching (PSM) was used to create weights for the observations to make the
113 three study groups equivalent in relation to the confounding variables [25]. The first analysis, used

114 to compare the symptoms between groups, included age, ethnicity, chronic cardiovascular disease,
115 asthma, diabetes, immunosuppression, and obesity. The second one, comparing the outcomes,
116 included the same variables plus schooling, Federative Unit of Brazil, and respiratory symptoms.
117 The analyses were performed with the statistical R software (R Foundation for Statistical Computing
118 Platform, version 4.0.3) [26] and PSM was carried out with the R WeightIt package [27].

119

120 Results

121 A total of 40,640 reproductive age women hospitalized with a positive RT-PCR for SARS-CoV-2 result
122 were identified. Of these, 3,372 were pregnant and 37,268 were not pregnant (Figure 1).
123 Nonpregnant women comprised 794 puerperal women and 36,474 women who were neither
124 pregnant nor puerperal. Groups differed significantly related to demographic data and
125 comorbidities (Table 1). The group of neither pregnant nor puerperal women had the highest rate
126 of comorbidities.

127

128 Figure 1: Study profile

129

130 **Table 1. Demographic and clinical characteristics of reproductive age women with COVID-19**
131 **according to gestational status – Brazil, February 17, 2020 – January 02, 2021**

Characteristics	Neither pregnant nor puerperal	Pregnant	Puerperal	p
Age (years)				
Mean ± SD	38.22 ± 8.25	29.64 ± 6.93	30.24 ± 7.34	<0.0001
Age bracket (years)	n (%)	n (%)	n (%)	
<20	1,009 (2.8)	250 (7.4)	61 (7.7)	<0.0001
20-34	9,629 (26.4)	2,244 (66.5)	494 (62.2)	
>34	2,5836 (70.8)	878 (26.0)	239 (30.1)	
Total	36,474	3,372	794	
Skin color/Ethnicity	n (%)	n (%)	n (%)	
White	15,418 (54.0)	1,102 (40.5)	238 (37.2)	<0.0001
Black	1,679 (5.9)	192 (7.1)	46 (7.2)	

Yellow	359 (1.3)	33 (1.2)	4 (0.6)	
Brown	10,976 (38.5)	1,382 (50.8)	348 (54.4)	
Indigenous	97 (0.3)	13 (0.5)	4 (0.6)	
Total	28,529 (100)	2,722 (100)	640 (100)	
Schooling	n (%)	n (%)	n (%)	
No schooling	219 (1.4)	7 (0.5)	2 (0.6)	
Up to high school	3,661 (23.7)	360 (25.1)	81 (24.5)	<0.0001
High school	7,532 (48.7)	790 (55.1)	179 (54.2)	
College	4,058 (26.2)	277 (19.3)	68 (20.6)	
Total	15,470 (100)	1,434 (100)	330 (100)	
Risk factors and comorbidities	n (%)	n (%)	n (%)	
Chronic cardiovascular disease (n=14,976)	5780/13,330 (43.4)	214/1,141 (18.8)	77/505 (15.2)	<0.0001
Chronic hematologic disease (n=12,901)	356/11,340 (3.1)	16/1,081 (1.5)	11/480 (2.3)	0.006
Chronic hepatic disease (n=12,769)	189/11,226 (1.7)	8/1,066 (0.8)	4/477 (0.8)	0.0273
Asthma (n=13,426)	1883/11,821 (15.9)	139/1,119 (12.4)	33/486 (6.8)	<0.0001
Diabetes (n=14,575)	4825/12,934 (37.3)	241/1,151 (20.9)	61/490 (12.4)	<0.0001
Chronic neurological disease (n=12,933)	568/11,377 (5.0)	25/1,078 (2.3)	5/478 (1.0)	<0.0001
Chronic lung disease (n=12,945)	579/11,390 (5.1)	23/1,075 (2.1)	5/480 (1.0)	<0.0001
Immunodepression (n=13,137)	1,289/11,578 (11.1)	40/1,078 (3.7)	18/481 (3.7)	<0.0001
Chronic renal disease (n=13,047)	1,080/11,495 (9.4)	24/1,073 (2.2)	12/479 (2.5)	<0.0001
Obesity (n=13,713)	3,741/12,135 (30.8)	143/1,097 (13.0)	53/481 (11.0)	<0.0001
Metabolic syndrome (n=12,509)	422/10,998 (3.8)	7/1,044 (0.7)	7/467 (1.5)	<0.0001
Number of comorbidities (n=11,958)	n (%)	n (%)	n (%)	< 0.0001
0	2,022/10,502 (19.3)	576/999 (57.7)	335/457 (73.3)	
1-2	7,681/10,502 (73.1)	408/999 (40.8)	106/457 (23.2)	
>2	799/10,502 (7.6)	15/999 (1.5)	16/457 (3.5)	

132

133

134 Table 2 shows the results of the comparison of COVID-19 symptoms before and after PSM in the
 135 three study groups. Both pregnant and puerperal women had a smaller chance of fever, cough, sore
 136 throat, dyspnea, respiratory discomfort, SpO₂<95%, diarrhea, vomiting, fatigue, SARI, and SARI
 137 without fever than neither pregnant nor puerperal women. Pregnant women had anosmia and
 138 ageusia more frequently than the others. Puerperal women had fewer chance of fever, coughing,
 139 vomiting, SARI, and SARI without fever than pregnant women; however, their oxygen saturation
 140 level was more frequently lower than 95% at hospital admission.

141

142

143 **Table 2. COVID-19 signs, symptoms, and infection in pregnant, puerperal, and neither pregnant**
 144 **nor puerperal reproductive age women before and after propensity score matching –**

145 **Brazil, February 17, 2020 – January 02, 2021**

Signs, symptoms, and infection	Neither pregnant nor puerperal	Pregnant	Puerperal	Group comparison			Group comparison after PSM (age + ethnicity + cardiopathy + asthma + diabetes + immunosuppression + obesity)		
	n (%)	n (%)	n (%)	Pregnant vs. NPrNPu OR (95% CI)	Puerperal vs. NPrNPu OR (95% CI)	Puerperal vs. Pregnant OR (95% CI)	Pregnant vs. NPrNPu OR (95% CI)	Puerperal vs. NPrNPu OR (95% CI)	Puerperal vs. Pregnant OR (95% CI)
Fever (n=36,371)	24,297/32,702 (74.3)	2,038/2,983 (68.3)	424/686 (61.8)	0.75 (0.69 - 0.81)	0.56 (0.48 - 0.65)	0.75 (0.63 - 0.89)	0.78 (0.69 - 0.88)	0.63 (0.53 - 0.74)	0.81 (0.67 - 0.93)
Cough (n=37,101)	27,305/33,324 (81.9)	2,408/3,085 (78.1)	475/692 (68.6)	0.78 (0.72 - 0.86)	0.48 (0.41 - 0.57)	0.62 (0.51 - 0.74)	1.19 (1.04 - 1.36)	0.81 (0.67 - 0.97)	0.68 (0.56 - 0.82)
Sore throat (n=31,474)	8,854/28,242 (31.4)	724/2,629 (27.5)	156/603 (25.9)	0.83 (0.76 - 0.91)	0.76 (0.63 - 0.92)	0.92 (0.75 - 1.12)	0.88 (0.78 - 1.01)	0.90 (0.74 - 1.10)	1.02 (0.83 - 1.26)
Dyspnea (n=36,272)	25,134/32,664 (76.9)	1,761/2,940 (59.9)	381/668 (57.0)	0.45 (0.41 - 0.48)	0.40 (0.34 - 0.47)	0.89 (0.75 - 1.05)	0.54 (0.48 - 0.61)	0.54 (0.45 - 0.64)	1.00 (0.84 - 1.20)
Respiratory discomfort (n=34,023)	20,158/30,600 (65.9)	1,374/2,771 (49.6)	341/652 (52.3)	0.51 (0.47 - 0.55)	0.57 (0.49 - 0.66)	1.11 (0.94 - 1.32)	0.60 (0.54 - 0.68)	0.73 (0.62 - 0.87)	1.21 (1.02 - 1.45)
SpO ₂ <95% (n=33,482)	17,109/30,137 (56.8)	860/2,708 (31.8)	291/637 (45.7)	0.35 (0.32 - 0.39)	0.64 (0.55 - 0.75)	1.81 (1.52 - 2.15)	0.40 (0.35 - 0.45)	0.79 (0.67 - 0.94)	1.99 (1.65 - 2.39)
At least 1 respiratory symptom (n=37,726)	30,208/34,002 (88.8)	2,177/3,021 (72.1)	490/703 (69.7)	0.32 (0.30 - 0.35)	0.29 (0.25 - 0.34)	0.89 (0.75 - 1.07)	0.44 (0.38 - 0.51)	0.43 (0.36 - 0.53)	0.98 (0.81 - 1.18)
Diarrhea (n=30,907)	6,387/27,758 (23.0)	335/2,574 (13.0)	65/575 (11.3)	0.50 (0.44 - 0.56)	0.43 (0.33 - 0.55)	0.85 (0.64 - 1.13)	0.61 (0.52 - 0.71)	0.53 (0.41 - 0.70)	0.88 (0.66 - 1.18)
Vomiting (n=30,342)	4,148/27,206 (15.2)	342/2,566 (13.3)	45/570 (7.9)	0.86 (0.76 - 0.96)	0.48 (0.35 - 0.64)	0.56 (0.40 - 0.77)	0.75 (0.63 - 0.89)	0.47 (0.34 - 0.64)	0.63 (0.45 - 0.87)
Abdominal pain (n=15,775)	13.47/14,360 (9.4)	117/1,175 (10.0)	20/240 (8.3)	1.07 (0.87 - 1.30)	0.88 (0.54 - 1.37)	0.83 (0.49 - 1.33)	0.94 (0.69 - 1.28)	0.75 (0.45 - 1.24)	0.80 (0.48 - 1.33)
Fatigue (n=16,216)	4,383/14,780 (29.7)	263/1,191 (22.1)	47/245 (19.2)	0.67 (0.58 - 0.77)	0.56 (0.41 - 0.77)	0.84 (0.59 - 1.18)	0.95 (0.78 - 1.15)	0.86 (0.61 - 1.20)	0.90 (0.63 - 1.29)
Anosmia (n=16,202)	3,216/14,718 (21.9)	335/1,224 (27.4)	51/260 (19.6)	1.35 (1.18 - 1.54)	0.87 (0.64 - 1.18)	0.65 (0.46 - 0.90)	1.79 (1.48 - 2.17)	1.26 (0.91 - 1.75)	0.70 (0.50 - 0.99)
Ageusia (n=16,103)	3,121/14,634 (21.3)	297/1,212 (24.5)	45/257 (17.5)	1.20 (1.04 - 1.37)	0.79 (0.56 - 1.08)	0.66 (0.46 - 0.92)	1.70 (1.41 - 2.04)	1.17 (0.84 - 1.64)	0.69 (0.48 - 0.99)
SARI (n=34,118)	18,089/30,689 (58.9)	1,308/2,795 (46.8)	242/634 (38.2)	0.61 (0.57 - 0.66)	0.43 (0.37 - 0.51)	0.70 (0.59 - 0.84)	0.78 (0.70 - 0.88)	0.58 (0.49 - 0.69)	0.74 (0.62 - 0.89)
SARI without fever (n=35,939)	24,504/32,353 (75.7)	1,816/2,925 (62.1)	351/661 (53.1)	0.52 (0.48 - 0.57)	0.36 (0.31 - 0.42)	0.69 (0.58 - 0.82)	0.75 (0.67 - 0.85)	0.57 (0.48 - 0.67)	0.75 (0.63 - 0.90)
Hospital-acquired infection (n=30,722)	760/27,508 (2.8)	37/2,617 (1.4)	34/597 (5.7)	0.51 (0.36 - 0.70)	2.13 (1.47 - 2.99)	4.21 (2.61 - 6.78)	0.38 (0.24 - 0.59)	1.28 (0.85 - 1.93)	3.38 (2.01 - 5.69)

146 PSM, Propensity Score Matching; NPrNPu, neither pregnant nor puerperal; OR, Odds Ratio; 95%CI, 95% confidence
 147 interval; SpO₂, oxygen saturation in room air; SARI, temperature ≥ 38°C, cough, and onset in 10 days
 148

149

							CI)	CI)	CI)	CI)
ICU admission (n=32,769)		8014/29,368 (27.3)	574/2,721 (21.1)	244/680 (35.9)	0.71 (0.65 – 0.78)	1.49 (1.27 – 1.75)	2.09 (1.74 – 2.51)	0.58 (0.48 – 0.71)	1.14 (0.91 – 1.43)	1.97 (1.62 – 2.40)
Ventilatory support (n=31,457)	No	n=28,199	n=2,598	n=660						
	Yes, invasive	3,536 (12.5)	209 (8.0)	133 (20.2)	0.42 (0.36 - 0.48)	1.23 (1.00 – 1.51)	2.96 (2.31 – 3.79)	0.48 (0.33 - 0.68)	1.29 (0.96 - 1.74)	2.71 (1.91 - 3.82)
	Yes, noninvasive	13,213 (46.9)	763 (29.4)	178 (27.0)	0.41 (0.37 – 0.44)	0.44 (0.37 – 0.53)	1.09 (0.89 – 1.33)	0.59 (0.47 - 0.75)	0.65 (0.51 - 0.83)	1.10 (0.86 - 1.42)
Death (n=35,700)		4,534/32,081 (14.1)	181/2,904 (6.2)	114/715 (15.9)	0.40 (0.34 – 0.47)	1.15 (0.94 – 1.41)	2.85 (2.22 – 3.66)	0.43 (0.34 – 0.54)	1.09 (0.86 – 1.38)	2.51 (1.90 – 3.31)

170 PSM, Propensity Score Matching; NPrNPu, neither pregnant nor puerperal; OR, Odds Ratio; 95%CI, 95%
 171 confidence interval; FUB, Federative Unit of Brazil; ICU, Intensive Care Unit
 172

173 After PSM (with the inclusion schooling, Federative Unit of Brazil, and respiratory symptoms
 174 variables), the only difference between this analysis and the general analysis was that puerperal
 175 women were no longer more likely than neither pregnant nor puerperal women to be admitted to
 176 ICU, while maintaining a worse prognosis than that of pregnant women with respect to admission
 177 to the ICU, invasive ventilatory support, and death.

178 Pregnant women with chronic cardiovascular or renal disease, asthma, diabetes,
 179 immunodepression, or obesity, and those in the ICU, or those who received ventilatory support
 180 were less likely to die than neither pregnant nor puerperal women with the same characteristics
 181 (Table 4). Puerperal women did not differ significantly from neither pregnant nor puerperal
 182 regarding the study variables. Puerperal women had a greater likelihood of dying than pregnant
 183 women when both had asthma, diabetes, or obesity, or when received noninvasive ventilatory
 184 support, or were admitted to the ICU. After PSM, of women with chronic cardiovascular disease or
 185 diabetes and of those admitted to ICU or who received noninvasive support, pregnant were less
 186 likely to die than neither pregnant nor puerperal women.

187

188 **Table 4. Comparison of the death rates of pregnant, puerperal, and neither pregnant nor**
 189 **puerperal reproductive age women before and after propensity score matching according to**
 190 **comorbidities, ICU admission, and ventilatory support – Brazil, February 17, 2020 – January 02,**
 191 **2021**

Variable	Death rate			Group comparison			Group comparison after PSM (age + ethnicity + schooling + FUB + chronic cardiovascular disease + asthma + diabetes + immunosuppression + obesity + respiratory symptoms)		
	Neither pregnant nor puerperal	Pregnant	Puerperal	Pregnant vs. NPrNPu OR (95% CI)	Puerperal vs. NPrNPu OR (95% CI)	Puerperal vs. Pregnant OR (95% CI)	Pregnant vs. NPrNPu OR (95% CI)	Puerperal vs. NPrNPu OR (95% CI)	Puerperal vs. Pregnant OR (95% CI)
Chronic cardiovascular disease (n=5,349)	1,159/5,093 (22.8)	24/186 (12.9)	15/70 (21.4)	0.51 (0.32 – 0.77)	0.93 (0.51 – 1.62)	1.84 (0.88 – 3.75)	0.47 (0.28 – 0.79)	0.96 (0.52 – 1.75)	2.02 (0.97 – 4.24)
Asthma (n=1,804)	254/1,658 (15.3)	8/119 (6.7)	6/27 (22.2)	0.41 (0.18 – 0.79)	1.61 (0.58 – 3.82)	3.93 (1.16 – 12.75)	0.56 (0.20 – 1.59)	2.68 (0.99 – 7.20)	4.79 (1.27 – 18.02)
Diabetes (n=4,539)	1,143/4,268 (26.8)	27/212 (12.7)	19/59 (32.2)	0.40 (0.26 – 0.59)	1.30 (0.73 – 2.23)	3.24 (1.62 – 6.41)	0.43 (0.26 – 0.72)	1.52 (0.85 – 2.70)	3.50 (1.70 – 7.22)
Immunodepression (n=1,213)	408/1,159 (35.2)	6/36 (16.7)	3/18 (16.7)	0.38 (0.14 – 0.85)	0.38 (0.08 – 1.18)	1.02 (0.18 – 4.62)	0.54 (0.19 – 1.48)	0.55 (0.15 – 1.98)	1.03 (0.21 – 5.01)
Chronic Renal disease (n=995)	385/963 (40.0)	2/21 (9.5)	4/11 (36.4)	0.17 (0.02 – 0.59)	0.87 (0.22 – 2.98)	4.96 (0.74 – 47.5)	0.59 (0.12 – 2.82)	1.52 (0.41 – 5.65)	2.56 (0.37 – 17.61)
Obesity (n= 3,500)	762/3,327 (22.9)	19/125 (15.2)	15/48 (31.2)	0.61 (0.36 – 0.97)	1.54 (0.80 – 2.80)	2.52 (1.14 – 5.55)	0.80 (0.42 – 1.53)	2.29 (1.22 – 4.30)	2.84 (1.19 – 6.78)
Invasive respiratory support (n=3,878)	2,249/3,536 (63.6)	104/209 (49.8)	77/133 (57.9)	0.57 (0.43 – 0.75)	0.79 (0.55 – 1.12)	1.39 (0.89 – 2.16)	0.68 (0.38 – 1.21)	0.83 (0.46 – 1.48)	1.22 (0.75 – 1.99)
Noninvasive respiratory support (n=14,154)	1246/13,213 (9.4)	37/763 (4.8)	18/178 (10.1)	0.49 (0.35 – 0.69)	1.09 (0.64 – 1.73)	2.21 (1.20 – 3.95)	0.48 (0.30 – 0.77)	0.92 (0.53 – 1.60)	1.93 (1.02 – 3.63)
ICU admission (n=8,832)	2,755/8,014 (34.4)	127/574 (22.1)	90/244 (36.9)	0.54 (0.44 – 0.66)	1.12 (0.85 – 1.45)	2.06 (1.48 – 2.85)	0.69 (0.48 – 0.99)	1.27 (0.88 – 1.83)	1.84 (1.28 – 2.64)

192 PSM, Propensity Score Matching; NPrNPu, neither pregnant nor puerperal; OR, Odds Ratio; 95%CI, 95%
 193 confidence interval; FUB, Federative Unit of Brazil; ICU, Intensive Care Unit

194

195 Discussion

196 The results of the current analysis show that at hospital admission, both pregnant and puerperal
 197 women, in general, presented a lower rate of symptoms than neither pregnant nor puerperal
 198 women, except for cough, anosmia, and ageusia of pregnant women. On the other hand, the

199 contrast between puerperal and pregnant women revealed that the former had a higher rate of
200 respiratory discomfort and $SpO_2 < 95\%$, as well as a higher likelihood of ICU admission, invasive
201 ventilatory support, and death. Therefore, our study data suggest that puerperal women are at a
202 higher risk of severe outcomes than pregnant women and run as much risk as neither pregnant nor
203 puerperal women.

204 At the beginning of the COVID-19 pandemic, the initial publications addressing infections in
205 pregnant women were case reports, short case series, and systematic reviews. Given the low case
206 numbers, the first impression was that pregnant and puerperal women were not at a higher risk for
207 complications and death than the non-obstetric population [3-9]. As epidemiological weeks passed,
208 new studies reported a greater need for invasive ventilation and ICU and an increased number of
209 deaths in the obstetric population [10,11,13,14,16,28].

210 The United States Centers for Disease Control and Prevention published data from January 22 to
211 October 3, 2020, comprising 1,300,938 women with COVID-19. Of these, 23,434 were symptomatic
212 pregnant women. In that study, pregnant women, as opposed to nonpregnant, ran a higher risk of
213 ICU admission, invasive ventilation, extracorporeal membrane oxygenation (ECMO), and death
214 [13]. In our study, the sample included only hospitalized women with SARS-CoV-2. After PSM, our
215 results differed from the CDC results as follows: pregnant women were less likely to be admitted to
216 an ICU (OR 0.58), to need invasive ventilation (OR 0.48), or to die (OR 0.43) than nonpregnant;
217 however, puerperal women were at a higher risk of death than pregnant women. Among all the
218 signs and symptoms reported in the CDC study, cough, headache, myalgia, and fever were the most
219 common and they were mostly reported by the nonpregnant women [13]. Our data also show that
220 the most common signs and symptoms in all groups were cough, dyspnea, and fever, with both
221 pregnant and puerperal women showing fewer symptoms than nonpregnant women. Nevertheless,

222 pregnant women had anosmia and dysgeusia significantly more frequently than the other two
223 groups.

224 In a study with the Brazilian population involving 2,475 pregnant and puerperal women with SARS,
225 72% of whom had COVID-19 confirmed by RT-PCR, 590 had unfavorable outcomes. The risk
226 increased 2.4 times when the SARS notification occurred in the postpartum period rather than
227 during pregnancy [21]. In the present study, all cases were confirmed by RT-PCR, and the
228 unfavorable outcomes (ICU, mechanical ventilation, and death) were analyzed separately for each
229 group of women (pregnant, puerperal, and neither pregnant nor puerperal) to identify the specific
230 risks for each outcome and each group. After pairing with PSM, puerperal women were more likely
231 than pregnant women to be admitted to ICU (OR 1.97), to receive invasive respiratory support (OR
232 2.71), to die (OR 2.51), and to acquire the COVID-19 infection in hospital (OR 3.38).

233 In Mexico, a study including a cohort of 5,183 pregnant women and 175,905 nonpregnant women
234 with COVID-19 compared the two groups regarding death, pneumonia, invasive respiratory
235 support, and ICU admission. The data (comorbidities, age, language, and health insurance level)
236 were analyzed with and without adjustment for propensity score matching. After pairing, pregnant
237 women showed a higher likelihood of death (OR 1.84), pneumonia (OR 1.86), and ICU admission
238 (OR 1.86) than nonpregnant, but both groups ran a similar risk of invasive respiratory support (OR
239 0.93) [14]. The study, however, did not evaluate either group separately. In contrast to the Mexican
240 study, our data, following adjustments, revealed that pregnant women had a lower likelihood of
241 death (OR 0.43), invasive respiratory support (OR 0.48), and ICU admission (OR 0.58) than both
242 neither pregnant nor puerperal women and puerperal women. It should be mentioned that the two
243 studies are not comparable, given that the Mexican study, on the one hand, included women who
244 were not hospitalized and, on the other hand, divided reproductive age women into only two
245 groups, pregnant and nonpregnant.

246 Our study has the following strong points: 1) the use of a national database with a large sample size
247 number and no duplicates; 2) patients who were hospitalized due to severe acute respiratory
248 syndrome, which was confirmed by the RT-PCR laboratory test; 3) discrimination between pregnant
249 and puerperal women for a more accurate analysis of the obstetric population; 4) the use of paired
250 comparison analysis through propensity score matching, which allowed adjustments for the
251 demographic data and comorbidities to evaluate symptoms and outcomes.

252 As study limitations, a comparison with those infected with COVID-19 in the general population
253 could not be made because only hospitalized cases with SARS and deaths are notified, and bias
254 introduced by missing variables cannot be eliminated.

255 In the present study, the death risk of each comorbidity was identified separately for the three
256 groups of women: pregnant, puerperal, and neither pregnant nor puerperal. This enabled the use
257 of ORs included in the risk calculations for the COVID-19 progression at hospital admission.

258 Since puerperal women were at a higher risk for the most severe outcomes (need for ICU, use of
259 invasive ventilatory support, and death), the fact that pregnancy is over must not underestimate
260 the severity risks. Thus, in those cases in which the SARS-CoV-2 infection is acquired at the end of
261 pregnancy, the delivery should be considered only after overcoming the disease. When it is
262 acquired during the puerperal period, health professionals should remain alert to the severity-
263 related risks. It would be ideal if all women were vaccinated to minimize the risks of SARS-CoV-2
264 infection and if they adhered to protection measures to prevent contamination by the virus.

265 As puerperal turned out to be a higher risk group than pregnant women among those hospitalized
266 due to COVID-19, we need more studies comparing these groups. Furthermore, it should be
267 considered that childbirth might influence the progression of COVID-19.

268

269 **Data availability statement**

270 The data that support the findings of this study are available in GitHub repository at
271 https://github.com/observatorioobstetrico/paper_covid19_groups. These data were derived from
272 the following resources available in the public domain:
273 <https://opendatasus.saude.gov.br/dataset/bd-srag-2020> obtained on January 11, 2021.

274

275 **Acknowledgments**

276 This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation [INV-027961].
277 Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License
278 has already been assigned to the Author Accepted Manuscript version that might arise from this
279 submission.

280

281 **References**

- 282 1. World Health Organization. WHO Director-General's opening remarks at the media briefing on
283 COVID-19 - 11 March 2020. Available from: [https://www.who.int/director-](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)
284 [general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)
285 [19---11-march-2020](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)
- 286 2. WHO COVID-19 Dashboard [Internet]. Geneva: World Health Organization, 2021 - [cited 2021
287 Jun 28]. Available from: <https://covid19.who.int/>
- 288 3. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine
289 vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective
290 review of medical records. *Lancet*. 2020;395(10226):809-815.
- 291 4. Mullins E, Evans D, Viner RM, O'Brien P, Morris E. Coronavirus in pregnancy and delivery: rapid
292 review. *Ultrasound Obstet Gynecol*. 2020;55(5):586-592.

- 293 5. Kasraeian M, Zare M, Vafaei H, Asadi N, Faraji A, Bazrafshan K, et al. COVID-19 pneumonia and
294 pregnancy; a systematic review and meta-analysis. *J Matern Fetal Neonatal Med.* 2020;1-8.
- 295 6. Zaigham M, Andersson O. Maternal and perinatal outcomes with COVID-19: A systematic review
296 of 108 pregnancies. *Acta ObstetGynecolScand.* 2020;99(7):823-829.
- 297 7. Di Toro F, Gjoka M, Di Lorenzo G, De Santo D, De Seta F, Maso G, et al. Impact of COVID-19 on
298 maternal and neonatal outcomes: a systematic review and meta-analysis. *Clin Microbiol Infect.*
299 2021;27(1):36-46.
- 300 8. Elshafeey F, Magdi R, Hindi N, Elshebiny M, Farrag N, Mahdy S, et al. A systematic scoping review
301 of COVID-19 during pregnancy and childbirth. *Int J Gynaecol Obstet.* 2020;150(1):47-52.
- 302 9. Huntley BJF, Huntley ES, Di Mascio D, Chen T, Berghella V, Chauhan SP. Rates of Maternal and
303 Perinatal Mortality and Vertical Transmission in Pregnancies Complicated by Severe Acute
304 Respiratory Syndrome Coronavirus 2 (SARS-Co-V-2) Infection: A Systematic Review. *Obstet Gynecol.*
305 2020;136(2):303-312.
- 306 10. Sentilhes L, De Marcillac F, Jouffrieau C, Kuhn P, Thuet V, Hansmann Y, et al. Coronavirus
307 disease 2019 in pregnancy was associated with maternal morbidity and preterm birth. *Am J Obstet*
308 *Gynecol.* 2020;223(6):914.e1-914.e15.
- 309 11. Badr DA, Mattern J, Carlin A, Cordier AG, Maillart E, El Hachem L, et al. Are clinical outcomes
310 worse for pregnant women at ≥ 20 weeks' gestation infected with coronavirus disease 2019? A
311 multicenter case-control study with propensity score matching. *Am J Obstet Gynecol.*
312 2020;223(5):764-768.
- 313 12. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, risk
314 factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living
315 systematic review and meta-analysis. *BMJ.* 2020;370:m3320.

- 316 13. Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update: Characteristics
317 of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by
318 Pregnancy Status - United States, January 22-October 3, 2020. *MMWR Morb Mortal Wkly Rep.*
319 2020;69(44):1641-1647.
- 320 14. Martinez-Portilla RJ, Sotiriadis A, Chatzakis C, Torres-Torres J, Espino Y Sosa S, et al. Pregnant
321 women with SARS-CoV-2 infection are at higher risk of death and pneumonia: propensity score
322 matched analysis of a nationwide prospective cohort (COV19Mx). *Ultrasound Obstet Gynecol.*
323 2021;57(2):224-231.
- 324 15. Knight M, Bunch K, Vousden N, Morris E, Simpson N, Gale C, et al. Characteristics and outcomes
325 of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national
326 population-based cohort study. *BMJ.* 2020;369:m2107.
- 327 16. Hantoushzadeh S, Shamshirsaz AA, Aleyasin A, Seferovic MD, Aski SK, Arian SE, et al. Maternal
328 death due to COVID-19. *Am J Obstet Gynecol.* 2020;223(1):109.e1-109.e16.
- 329 17. Vallejo V, Ilagan JG. A Postpartum Death Due to Coronavirus Disease 2019 (COVID-19) in the
330 United States. *ObstetGynecol.* 2020;136(1):52-55.
- 331 18. Lumbreras-Marquez MI, Campos-Zamora M, Lizaola-Diaz de Leon H, Farber MK. Maternal
332 mortality from COVID-19 in Mexico. *Int J Gynaecol Obstet.* 2020;150(2):266-267.
- 333 19. Kayem G, Lecarpentier E, Deruelle P, Bretelle F, Azria E, Blanc J, et al. A snapshot of the Covid-19
334 pandemic among pregnant women in France. *J GynecolObstet Hum Reprod.* 2020;49(7):101826.
- 335 20. Takemoto MLS, Menezes MO, Andreucci CB, Nakamura-Pereira M, Amorim MMR, Katz L, et al.
336 The tragedy of COVID-19 in Brazil: 124 maternal deaths and counting. *Int J Gynaecol Obstet.*
337 2020;151(1):154-156.

- 338 21. Menezes MO, Takemoto MLS, Nakamura-Pereira M, Katz L, Amorim MMR, Salgado HO, et al.
339 Risk factors for adverse outcomes among pregnant and postpartum women with acute respiratory
340 distress syndrome due to COVID-19 in Brazil. *Int J Gynaecol Obstet.* 2020;151(3):415-423.
- 341 22. Amorim MMR, Soligo Takemoto ML, Fonseca EBD. Maternal deaths with coronavirus disease
342 2019: a different outcome from low- to middle-resource countries? *Am J Obstet Gynecol.*
343 2020;223(2):298-299.
- 344 23. Takemoto M, Menezes MO, Andreucci CB, Knobel R, Sousa L, Katz L, et al. Clinical characteristics
345 and risk factors for mortality in obstetric patients with severe COVID-19 in Brazil: a surveillance
346 database analysis. *BJOG.* 2020;127(13):1618-1626.
- 347 24. Brasil. Ministério da Saúde. Definição de Caso e Notificação. Available from:
348 <https://www.gov.br/saude/pt-br/coronavirus/artigos/definicao-e-casos-suspeitos>. Retrieved
349 04/04/2021.
- 350 25. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of
351 Confounding in Observational Studies. *Multivariate Behav Res.* 2011;46(3):399-424.
- 352 26. R Core Team. R: A language and environment for statistical computing. R Foundation for
353 Statistical Computing, Vienna, Austria, 2020. Version 4.0.3 [software]. 2020 Oct 10 [cited 2021 Jan
354 15]. Available from: <https://www.r-project.org/>
- 355 27. Greifer N. WeightIt: Weighting for Covariate Balance in Observational Studies. R package
356 version 0.10.2 [software]. 2020 Sep 20 [cited 2021 Jan 15]. Available from: [https://cran.r-](https://cran.r-project.org/package=WeightIt)
357 [project.org/package=WeightIt](https://cran.r-project.org/package=WeightIt)
- 358 28. Collin J, Byström E, Carnahan A, Ahrne M. Public Health Agency of Sweden's Brief Report:
359 Pregnant and postpartum women with severe acute respiratory syndrome coronavirus 2 infection
360 in intensive care in Sweden. *Acta ObstetGynecol Scand.* 2020;99(7):819-822.

